Revenue
2023
2024
2025
Radiopharm Theranostics Ltd (RADX)
Price—Loading quote
Net income
2023
2024
2025
Free cash flow
2023
Total cash / debt
CashTotal debt
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Revenue | $3.6M | $299,228 | $292,359 |
| Gross profit | $39,276 | $299,228 | $292,359 |
| Research & development | $27.5M | $23.1M | $22.6M |
| Operating income | −$38.2M | −$47.2M | −$34.5M |
| EBITDAderived | −$35.6M | −$44.1M | −$31.2M |
| Net income | −$38.3M | −$47.9M | −$34.6M |
| Basic EPSper diluted share | -$1.76 | -$12.41 | -$11.32 |
| Diluted EPSper diluted share | -$1.76 | -$12.41 | -$11.32 |